IHS FormWeb
Approved Formulary
Search by name
Search by class
Show Therapeutic Classes
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
IHS FormWeb
Approved Formulary
Search by name
Additional search options
Search by class
Show Therapeutic Classes
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Search results for:
rifAMPin
rifAMPin
Brand names:
Rifadin, Rifadin IV
Form
Strength
CAPSULE, ORAL
300 mg
POWDER FOR INJECTION, INTRAVENOUS
600 mg
SOLUTION, ORAL
150 mg/15 mL
Display
Antituberculosis Agents
Class:
081604
Medication comments:
Per policy, these drugs are subject to renal dosing adjustments by pharmacy.
Renal Dosing Program
View all
Generic + Route
(Brand)
• Indications
Usual Adult Dose
Comments
Renal Dosage Adjustments
rifAMPin
IV/PO
300-600 mg daily
No adjustment necessary
Per policy, these drugs may be converted from IV to PO in patients who meet criteria.
View all
rifampin
may convert from IV to PO on a mg-to-mg basis.
Last updated:
Oct. 16, 2024
Renal Adjustment Policy
rifAMPin subject to adjustments by pharmacy.
IV to PO Conversion Policy
Policy
Look-Alike/Sound-Alike
rifAMPin confused with Rifamate, rifAXIMin
UpToDate
FDA DailyMed Package Insert
MedLinePlus (Patient Information)
MSDS Online
UpToDate Lexidrug
(Brand)
• Indications
Comments